Published in Cancer Prev Res (Phila) on October 01, 2008
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med (2011) 1.93
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer (2012) 1.78
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care (2011) 1.65
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis (2012) 1.52
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle (2011) 1.46
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis (2012) 1.41
A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem (2009) 1.41
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle (2012) 1.41
Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res (2011) 1.38
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol (2010) 1.37
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
Metabolic alterations and targeted therapies in prostate cancer. J Pathol (2010) 1.28
Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol (2012) 1.24
Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle (2012) 1.22
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis (2013) 1.20
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun (2012) 1.19
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med (2014) 1.19
Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One (2014) 1.10
Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One (2014) 1.10
Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol (2011) 1.09
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res (2010) 1.06
The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci (2013) 1.05
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer (2010) 0.99
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget (2015) 0.94
Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. PLoS One (2012) 0.92
Caffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/Akt and AMPK signaling pathways. PLoS One (2014) 0.91
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo. PLoS One (2015) 0.91
The balance between leptin and adiponectin in the control of carcinogenesis - focus on mammary tumorigenesis. Biochimie (2012) 0.88
Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget (2011) 0.88
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int (2015) 0.85
Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res (2016) 0.85
Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res (Phila) (2014) 0.85
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene. J Cancer (2014) 0.83
Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression. Clin Exp Metastasis (2013) 0.83
Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog (2014) 0.83
Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell Int (2014) 0.81
Physical activity and its mechanistic effects on prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.80
Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget (2014) 0.78
A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Invest New Drugs (2014) 0.78
Metformin and cancer. Rev Diabet Stud (2014) 0.78
2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget (2017) 0.77
Metformin: Midlife maturity, maiden charm. Indian J Endocrinol Metab (2012) 0.77
Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade. J Biol Chem (2014) 0.77
Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Prev Res (Phila) (2015) 0.77
Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Exp Med (2015) 0.77
Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Front Pharmacol (2016) 0.76
No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study. BMC Cancer (2015) 0.76
Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate (2015) 0.76
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2. Endocr Relat Cancer (2016) 0.75
Fortifying the Treatment of Prostate Cancer with Physical Activity. Prostate Cancer (2016) 0.75
Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy. Inflammopharmacology (2016) 0.75
Effects of NSAIDs on the risk factors of colorectal cancer: a mini review. Genes Environ (2016) 0.75
Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. BMC Cancer (2016) 0.75
Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats. Mol Med Rep (2015) 0.75
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. Int J Endocrinol (2016) 0.75
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
Translational control in stress and apoptosis. Nat Rev Mol Cell Biol (2005) 8.91
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77
Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell (2009) 4.57
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (2007) 4.33
A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A (2001) 4.16
Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol (2002) 4.11
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell (2010) 4.01
Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev (2005) 3.92
The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol (2003) 3.90
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (2012) 3.82
eIF4E--from translation to transformation. Oncogene (2004) 3.78
Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature (2010) 3.77
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem (2005) 3.74
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell (2007) 3.46
The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol (2012) 3.42
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J (2004) 3.29
Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature (2012) 3.13
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell (2008) 3.10
Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol (2004) 3.00
14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta (2009) 2.89
Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 2.86
A new paradigm for translational control: inhibition via 5'-3' mRNA tethering by Bicoid and the eIF4E cognate 4EHP. Cell (2005) 2.80
Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol (2005) 2.80
Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature (2005) 2.67
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol (2008) 2.63
miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61
Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation. Cell (2009) 2.60
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol (2011) 2.58
Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol (2002) 2.53
A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J Cell Biol (2005) 2.51
A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation. J Biol Chem (2002) 2.43
mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol (2011) 2.41
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol (2004) 2.38
eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol (2004) 2.38
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci (2005) 2.33
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J (2007) 2.27
The dynamics of mammalian P body transport, assembly, and disassembly in vivo. Mol Biol Cell (2008) 2.25
Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell (2012) 2.19
The Akt of translational control. Oncogene (2005) 2.15
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2005) 2.15
Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev (2006) 2.14
Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA (2010) 2.11
Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) (2012) 2.10
Reconstitution reveals the functional core of mammalian eIF3. EMBO J (2007) 2.06
Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J Neurosci (2006) 2.04
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04
Activation of GCN2 in UV-irradiated cells inhibits translation. Curr Biol (2002) 2.02
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 2.01
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A (2005) 2.00
Two structurally atypical HEAT domains in the C-terminal portion of human eIF4G support binding to eIF4A and Mnk1. Structure (2006) 1.99
Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol (2005) 1.99
A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense-mediated decay. Proc Natl Acad Sci U S A (2004) 1.97
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev (2007) 1.95
A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics (2005) 1.95
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol (2006) 1.93
Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol (2002) 1.92
Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev (2002) 1.91
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol (2008) 1.88
La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol (2004) 1.87
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84
Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev (2005) 1.84
Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst (2013) 1.80
Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J (2006) 1.79
Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.75
S6K1 plays a critical role in early adipocyte differentiation. Dev Cell (2010) 1.74
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst (2012) 1.74
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Signaling control of mRNA translation in cancer pathogenesis. Oncogene (2004) 1.71
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat (2010) 1.67
Structural insights into the human GW182-PABC interaction in microRNA-mediated deadenylation. Nat Struct Mol Biol (2010) 1.66
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat (2012) 1.66
Dendritic BC1 RNA: functional role in regulation of translation initiation. J Neurosci (2002) 1.64
Poly(A) binding protein (PABP) homeostasis is mediated by the stability of its inhibitor, Paip2. EMBO J (2006) 1.64
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol (2011) 1.64
ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab (2008) 1.62